<DOC>
	<DOC>NCT01602939</DOC>
	<brief_summary>The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Cladribine plus Pegylated Interpheron alpha-2a therapy in patients with advanced systemic mastocytosis carrying D816V or other exon 17 KIT mutations.</brief_summary>
	<brief_title>Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis</brief_title>
	<detailed_description />
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis, Systemic</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Age older than 18 years. Diagnosis of advanced systemic mastocytosis (aggressive systemic mastocytosis or proggressing systemic mastocytosis) with D816V or other exon 17 KIT mutations. ECOG ≤ 3. Signed informed consent. Impaired liver function (total bilirubin ≥ 2.0 mg/dl, AST or ALT &gt; 3 x upper limit of normal)not related to mastocytosis. Impaired renal function (≥ 2.0 mg/dL)not related to mastocytosis. Grade IIIIV cytopenias not related to mastocytosis. Severe cardiopathy (grade III/IV of NYHA, or left ventricular ejection fraction &lt; 50%). Pregnancy or breastfeeding. Female patients who do not use contraceptive methods.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mast cell</keyword>
	<keyword>Mastocytosis</keyword>
	<keyword>Mast cell disease</keyword>
</DOC>